1
|
Frenel JS, Lusque A, Delaloge S, Ferrero JM, Bachelot T, Desmoulins I, Levy C, Eymard JC, Gonçalves A, Patsouris A, Reynier MAM, Thery MJC, Petit T, Cabel L, Uwer L, Debled M, Chevrot M, Mailliez A, Jacot W, de La Motte Rouge T. Efficacy of front-line treatment for hormone receptor-positive HER2-negative metastatic breast cancer with germline BRCA1/2 mutation. Br J Cancer 2023; 128:2072-2080. [PMID: 37012318 PMCID: PMC10205708 DOI: 10.1038/s41416-023-02248-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2022] [Revised: 03/06/2023] [Accepted: 03/20/2023] [Indexed: 04/05/2023] Open
Abstract
BACKGROUND Efficacy of endocrine therapy in HR+/HER2- metastatic breast cancer could differ depending on the presence of BRCA1/2 germline mutation. METHODS The ESME metastatic breast cancer platform (NCT03275311) is a French real world database. Multivariable models including a time-varying approach and landmark analyses assessed the association between time-dependent gBRCA status (categorised as gBRCAm, gBRCAwt (wild type), and untested), overall survival (OS), and first-line progression-free survival (PFS1). RESULTS A total of 170 patients were gBRCAm carriers, 676 gBRCAwt, and 12,930 were untested at baseline. In the multivariable analysis, gBRCAm carriers overall had a lower OS compared to gBRCAwt (adjusted HR [95% CI] 1.26 [1.03-1.55]). gBRCAm patients treated with front-line endocrine therapy had lower adjusted OS (adjusted HR [95% CI] = 1.54 [1.03-2.32]) and PFS1 (adjusted HR [95% CI] 1.58 [1.17-2.12]) compared to gBRCAwt patients. However, for patients who received frontline chemotherapy, neither OS nor PFS1 differed between gBRCAm carriers and the other groups (HR versus gBRCAwt for OS: 1.12 [0.88-1.41], p = 0.350; PFS1: 1.09 [0.90-1.31], p = 0.379). CONCLUSION In this large cohort of HR+/HER2- MBC patients treated in a pre-CDK4/6 inhibitors era, gBRCAm status was associated with a lower OS and lower PFS following first-line endocrine therapy, but not following first-line chemotherapy.
Collapse
Affiliation(s)
- J-S Frenel
- Medical Oncology, ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain, France.
| | - A Lusque
- Biostatistics & Health Data Science Unit, Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France
| | - S Delaloge
- Department of Cancer Medicine, Institut Gustave Roussy, Villejuif, France
| | - J-M Ferrero
- Medical Oncology, Centre Antoine Lacassagne, Nice, France
| | - T Bachelot
- Medical Oncology Department, Centre Léon Bérard, Lyon, France
| | - I Desmoulins
- Medical Oncology, Centre Georges-François Leclerc (Dijon), Dijon, France
| | - C Levy
- Medical Oncology, Centre Francois Baclesse, Caen, France
| | - J-C Eymard
- Medical Oncology, Institut Jean Godinot, Reims, France
| | - A Gonçalves
- Medical Oncology Department, Institute Paoli Calmettes, Marseille, France
| | - A Patsouris
- Medical Oncology Department, ICO - Institut de cancerologie de l'Ouest - Site Paul Papin, Angers, France
| | | | - M J-C Thery
- Medical Oncology, Centre Henri Becquerel, Rouen, France
| | - T Petit
- Bas-Rhin, Centre Paul Strauss Centre de Lutte contre le Cancer, Strasbourg, France
| | - L Cabel
- Medical Oncology, Hôpital René Huguenin - Institut Curie, Saint-Cloud, France
| | - L Uwer
- Medical Oncology, Institut de Cancerologie de Lorraine - Alexis Vautrin, Vandoeuvre Les Nancy, France
| | - M Debled
- Medical Oncology, Institut Bergonié, Bordeaux, France
| | - M Chevrot
- Department of Real World Data, UNICANCER, Paris, France
| | - A Mailliez
- Medical Oncology, Centre Oscar Lambret, Lille, France
| | - W Jacot
- Medical Oncology Department, ICM Regional Cancer Institute of Montpellier, Montpellier University, INSERM U1194, Montpellier, France
| | | |
Collapse
|
2
|
Vicier C, Isambert N, Cropet C, Hamimed M, Osanno L, Legrand F, de La Motte Rouge T, Ciccolini J, Gonçalves A. MOVIE: a phase I, open-label, multicenter study to evaluate the safety and tolerability of metronomic vinorelbine combined with durvalumab plus tremelimumab in patients with advanced solid tumors. ESMO Open 2022; 7:100646. [PMID: 36521418 PMCID: PMC9808477 DOI: 10.1016/j.esmoop.2022.100646] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2022] [Revised: 10/09/2022] [Accepted: 10/26/2022] [Indexed: 12/15/2022] Open
Abstract
BACKGROUND Anti-programmed cell death protein 1 (PD1)/programmed death-ligand 1 (PD-L1) agents have only moderate antitumor activity in some advanced solid tumors (AST), including breast cancer (BC), prostate cancer (PC), cervical cancer (CC), and head and neck cancer (HNC). Combining anti-PD-L1 with anti-cytotoxic T-lymphocyte-associated protein (CTLA) and chemotherapy may significantly improve efficacy. PATIENTS AND METHODS MOVIE is a multicohort phase I/II study examining the combination of anti-PD-L1 durvalumab (Durv; 1500 mg IV Q4W) plus anti-CTLA tremelimumab (Trem; 75 mg IV Q4W) with metronomic vinorelbine (MVino; 20-40 mg orally daily) in various AST resistant to conventional therapies. The primary objective of the phase I part was to determine the maximum tolerated dose (MTD) and recommended dose for phase II (RP2D). RESULTS Among the 14 patients enrolled during phase I, including 13 women and 1 man, 9 had BC, 1 PC, 2 CC, and 2 miscellaneous cancers with high mutational loads. Median age was 53 years. A total of 12 patients were assessable for the dose-escalation part in which only one dose-limiting toxicity (DLT) was observed [one neutropenia without fever, grade (G) 4]. Two (14.3%), four (28.6%), and four (28.6%) patients had G ≥3 adverse events (AEs) related to MVino, Durv, and Trem, respectively. Treatment-related events included mostly clinical AEs with asthenia (eight G2; three G3), colitis (one G2, one G3), diarrhea (one G3), nausea (two G2), dry skin (two G2), maculopapular rash (one G3), and hyperthyroidism (three G2). No toxic death was reported. Preliminary data showed one patient (CC) who presented a complete response and four patients with stable disease (SD). CONCLUSIONS MTD was not reached and dose level 2 (MVino 40 mg, Durv 1500 mg, Trem 75 mg) was selected as RP2D. The safety profile of the combination was manageable and consistent with previous reports of Trem + Durv or MVino. Phase II is currently ongoing in BC, PC, CC, HNC, and miscellaneous cohorts.
Collapse
Affiliation(s)
- C Vicier
- Department of Medical Oncology, Inserm U1068, CNRS UMR7258, Paoli-Calmettes Institute, Aix-Marseille University, Marseille, France
| | - N Isambert
- Service d'Oncologie médicale, CLCC Georges-François Leclerc, Dijon Cedex, France
| | - C Cropet
- Department of Biostatistics, Direction of Research and Innovation, Centre Léon Bérard, Lyon, France
| | - M Hamimed
- SMARTc unit, Centre de Recherche en Cancérologie de Marseille (CRCM) UMR INSERM U1068, Aix-Marseille University (AMU), Marseille, France
| | - L Osanno
- SMARTc unit, Centre de Recherche en Cancérologie de Marseille (CRCM) UMR INSERM U1068, Aix-Marseille University (AMU), Marseille, France
| | - F Legrand
- UNICANCER, Department of Research & Development, Paris, France
| | - T de La Motte Rouge
- Eugène-Marquis Centre, Avenue de la Bataille Flandres-Dunkerque, Rennes Cedex, France
| | - J Ciccolini
- SMARTc unit, Centre de Recherche en Cancérologie de Marseille (CRCM) UMR INSERM U1068, Aix-Marseille University (AMU), Marseille, France
| | - A Gonçalves
- Department of Medical Oncology, Inserm U1068, CNRS UMR7258, Paoli-Calmettes Institute, Aix-Marseille University, Marseille, France.
| |
Collapse
|
3
|
Heitz F, Valabrega G, Pothuri B, Oaknin A, Graybill W, Sánchez AB, McCormick C, Baurain JF, Hoskins P, Denys H, O’Cearbhaill RE, Hietanen S, Moore RG, Knudsen AØ, de La Motte Rouge T, Levy T, Li Y, Gupta D, Monk BJ, González-Martín A. Efficacy and safety of niraparib in older patients with advanced ovarian cancer (OC): results from the PRIMA/ENGOT-OV26/GOG-3012 trial. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1718222] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
- F Heitz
- Kliniken Essen-Mitte, Department for Gynecology and Gynecologic Oncology
| | - G Valabrega
- FPO-IRCCS Candiolo, Candiolo Cancer Institute
- University of Torino, Department of Oncology
| | - B Pothuri
- Gynecologic Oncology Group (GOG) and Perlmutter Cancer Center, NYU Langone Health, Department of Obstetrics/Gynecology
| | - A Oaknin
- Vall d´Hebron University Hospital and Vall d´Hebron Institute of Oncology (VHIO)
| | | | - AB Sánchez
- Hospital General Universitario de Elche, Unit of Genetic Counseling in Cancer, Medical Oncology Department
| | | | - JF Baurain
- Université Catholique de Louvain and Cliniques Universitaires Saint-Luc
| | - P Hoskins
- British Columbia Cancer Agency, Vancouver Centre, Medical Oncology
| | | | - RE O’Cearbhaill
- Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, Department of Medicine
| | - S Hietanen
- Turku University Hospital, Department of Obstetrics and Gynecology
| | - RG Moore
- University of Rochester, Division of Gynecologic Oncology, Wilmot Cancer Institute, Department of Obstetrics and Gynecology
| | | | | | - T Levy
- Wolfson Medical Center, Sackler School of Medicine, Tel Aviv University, Department of Obstetrics and Gynecology
| | | | | | - BJ Monk
- Arizona Oncology (US Oncology Network), University of Arizona College of Medicine
| | - A González-Martín
- Grupo Español de Investigación en Cáncer de Ovario (GEICO) and Clínica Universidad de Navarra, Medical Oncology Department
| |
Collapse
|
4
|
Gonçalves A, de La Motte Rouge T, Bruno A, Isambert N, Hervieu A, Legrand F, Cropet C. 555P Metronomic oral vinorelbine (MOV) combined with tremelimumab (T) + durvalumab (D) in advanced solid tumours (AST): Dose finding results. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.669] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
5
|
Francois A, Lusque A, Levy C, Pistilli B, Brain E, Pasquier D, Debled M, Thery J, Gonçalves A, Desmoulins I, de La Motte Rouge T, Faure C, Ferrero JM, Eymard JC, Reynier MM, Petit T, Payen O, Uwer L, Guiu S, Frenel JS. 306P Real-life management and prognosis of young women (≤ 40 yo) with de novo metastatic breast cancer in the multicenter national observational ESME program. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.408] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022] Open
|
6
|
de La Motte Rouge T, Bengrine Lefevre L, Mouret-Reynier MA, Asselain B, Lucas B, Gavoille C, Cornila C, Spaeth D, Colomba E, Patsouris A, Fabbro M, Chakiba C, Toussaint P, Simon H, Berton D, Garbay D, Garnier Tixidre C, Coeffic D, Collard O, Lefeuvre-Plesse C. 823P Extended follow-up of a real-world cohort of patients (pts) with BRCA mutation (BRCAm) relapsed epithelial ovarian cancer (EOC) receiving olaparib maintenance therapy: The GINECO RETROLA study. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.962] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
7
|
Frenel JS, Dalenc F, Pistilli B, de La Motte Rouge T, Levy C, Mouret-Reynier MA, Hardy-Bessard AC, Bonichon-Lamichhane N, Greilsamer C, Delecroix V, Nguyen S, Berger F, Everhard S, Lemonnier J, Loirat D, Callens C, Pradines A, Bachelot T, Delaloge S, Bidard F. 304P ESR1 mutations and outcomes in BRCA1/2 or PALB2 germline mutation carriers receiving first line aromatase inhibitor + palbociclib (AI+P) for metastatic breast cancer (MBC) in the PADA-1 trial. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.406] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
8
|
Valabrega G, Pothuri B, Oaknin A, Graybill W, Sánchez A, Mccormick C, Baurain JF, Hoskins P, Denys H, O’Cearbhaill R, Heitanen S, Moore R, Knudsen A, de La Motte Rouge T, Heitz F, Levy T, Li Y, Gupta D, Monk B, Martín AG. 819P Efficacy and safety of niraparib in older patients (pts) with advanced ovarian cancer (OC): Results from the PRIMA/ENGOT-OV26/GOG-3012 trial. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.958] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
9
|
Derquin F, Floquet A, Hardy-Bessard AC, Edeline J, Lotz JP, Alexandre J, Pautier P, Angeles MA, Delanoy N, Lefeuvre-Plesse C, Cancel M, Treilleux I, Augereau P, Lavoue V, Kalbacher E, Berton Rigaud D, Selle F, Nadeau C, Gantzer J, Joly F, Guillemet C, Pomel C, Favier L, Abdeddaim C, Venat-Bouvet L, Provansal M, Fabbro M, Kaminsky MC, Lortholary A, Lecuru F, Coquard IR, de La Motte Rouge T. Need for risk-adapted therapy for malignant ovarian germ cell tumors: A large multicenter analysis of germ cell tumors' patients from French TMRG network. Gynecol Oncol 2020; 158:666-672. [PMID: 32624235 DOI: 10.1016/j.ygyno.2020.06.491] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2020] [Accepted: 06/12/2020] [Indexed: 02/07/2023]
Abstract
BACKGROUND Malignant ovarian germ cell tumors are rare tumors, affecting young women with a generally favorable prognosis. The French reference network for Rare Malignant Gynecological Tumors (TMRG) aims to improve their management. The purpose of this study is to report clinicopathological features and long-term outcomes, to explore prognostic parameters and to help in considering adjuvant strategy for stage I patients. PATIENTS AND METHODS Data from patients with MOGCT registered among 13 of the largest centers of the TMRG network were analyzed. We report clinicopathological features, estimated 5-year event-free survival (5y-EFS) and 5-year overall survival (5y-OS) of MOGCT patients. RESULTS We collected data from 147 patients including 101 (68.7%) FIGO stage I patients. Histology identifies 40 dysgerminomas, 52 immature teratomas, 32 yolk sac tumors, 2 choriocarcinomas and 21 mixed tumors. Surgery was performed in 140 (95.2%) patients and 106 (72.1%) received first line chemotherapy. Twenty-two stage I patients did not receive chemotherapy. Relapse occurred in 24 patients: 13 were exclusively treated with upfront surgery and 11 received surgery and chemotherapy. 5y-EFS was 82% and 5y-OS was 92.4%. Stage I patients who underwent surgery alone had an estimated 5y-EFS of 54.6% and patients receiving adjuvant chemotherapy 94.4% (P < .001). However, no impact on estimated 5y-OS was observed: 96.3% versus 97.8% respectively (P = .62). FIGO stage, complete primary surgery and post-operative alpha fetoprotein level significantly correlated with survival. CONCLUSION Adjuvant chemotherapy does not seem to improve survival in stage I patients. Active surveillance can be proposed for selected patients with a complete surgical staging.
Collapse
Affiliation(s)
- F Derquin
- Medical Oncology Department, Centre Hospitaliser Yves Le Foll, Saint Brieuc, France
| | - A Floquet
- Medical Oncology Department, Institut Bergonié, Bordeaux, France
| | | | - J Edeline
- Medical Oncology Department, Centre Eugène Marquis, Rennes, France
| | - J P Lotz
- Medical Oncology Department, Sorbonne University, APHP, Paris, France
| | - J Alexandre
- Medical Oncology Department, Hôpital Cochin, APHP, Paris, France
| | - P Pautier
- Medical Oncology Department, Institut Gustave Roussy, Villejuif, France
| | - M A Angeles
- Surgical Oncology Department, Institut Claudius Regaud, Toulouse, France
| | - N Delanoy
- Medical Oncology Department, Hôpital Européen Georges Pompidou, APHP, Paris, France
| | | | - M Cancel
- Medical Oncology Department, Centre Hospitalier Universitaire Bretonneau, Tours, France
| | - I Treilleux
- Medical Oncology Department, Centre Léon Bérard, Lyon, France
| | - P Augereau
- Medical Oncology Department, Institut de Cancérologie de l'Ouest, Angers, France
| | - V Lavoue
- Gynecology Department, Centre Hospitalier Universitaire, Rennes, France
| | - E Kalbacher
- Medical Oncology Department, Centre Hospitalier Régional Universitaire, Besançon, France
| | - D Berton Rigaud
- Medical Oncology Department, Institut de Cancérologie de l'Ouest, Nantes, France
| | - F Selle
- Diaconnesses Hospital Group, Paris, France
| | - C Nadeau
- Gynecology Department, CHU de Poitiers, Poitiers, France
| | - J Gantzer
- Medical Oncology Department, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
| | - F Joly
- Medical Oncology Department, Centre François Baclesse, Caen, France
| | - C Guillemet
- Medical Oncology Department, Centre Henri-Becquerel, Rouen, France
| | - C Pomel
- Medical Oncology Department, Centre Jean Perrin, Clermont-Ferrand, France
| | - L Favier
- Medical Oncology Department, Centre Georges François Leclerc, Dijon, France
| | - C Abdeddaim
- Medical Oncology Department, Centre Oscar Lambret, Lille, France
| | - L Venat-Bouvet
- Medical Oncology Department, CHU Dupuytren, Limoges, France
| | - M Provansal
- Medical Oncology Department, Institut Paoli Calmettes, Marseille, France
| | - M Fabbro
- Medical Oncology Department, Institut régional du Cancer Montpellier, Montpellier, France
| | - M C Kaminsky
- Medical Oncology Department, Institut de Cancérologie de Lorraine - Alexis Vautrin, Vandoeuvre-Les-Nancy, France
| | - A Lortholary
- Medical Oncology Department, Hôpital Privé du Confluent, Nantes, France
| | - F Lecuru
- Medical Oncology Department, Hôpital Européen Georges Pompidou, APHP, Paris, France
| | - I Ray Coquard
- Medical Oncology Department, Centre Léon Bérard, Lyon, France
| | | |
Collapse
|
10
|
de La Motte Rouge T, Eisinger F, Couraud S, Greillier L, Touboul C, Lhomel C, Rouprêt M, Viguier J, Morere JF. Who drops out of cervical cancer screening? Results from the EDIFICE 6 survey. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz250.053] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
11
|
Bidard FC, Callens C, Pistilli B, Dalenc F, de La Motte Rouge T, Sabatier R, Frenel JS, Ladoire S, Dubot C, Ferrero JM, Clatot F, Nierges D, Everhard S, Lemonnier J, Bieche I, Pradines A, Pierga JY, Berger F, Bachelot T, Delaloge S. Emergence of ESR1 mutation in cell-free DNA during first line aromatase inhibitor and palbociclib: An exploratory analysis of the PADA-1 trial. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz242.002] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
12
|
Couraud S, Morère J, Viguier J, Roupret M, Brignoli-Guibaudet L, Lhomel C, de La Motte Rouge T, Eisinger F, Greillier L. Social and behavioral indicators of undergoing a screening test for lung cancer. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy424.060] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
13
|
Morere JF, Viguier J, Greillier L, Roupret M, Touboul C, Lhomel C, Couraud S, de La Motte Rouge T, Eisinger F. Indicators of non-uptake of breast cancer screening: Results from the EDIFICE 6 survey. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy424.080] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
14
|
Viguier J, Morère J, Couraud S, Roupret M, Touboul C, Lhomel C, Greillier L, de La Motte Rouge T, Eisinger F. Profile of individuals who never undergo colorectal cancer screening. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy424.026] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
15
|
de La Motte Rouge T, Couraud S, Eisinger F, Roupret M, Brignoli-Guibaudet L, Lhomel C, Greillier L, Viguier J, Morère J. Indicators of non-participation in cervical cancer screening: Results from the EDIFICE 6 survey. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy424.044] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
16
|
de La Motte Rouge T, Cottu P, Pautier P, Provansal M, Floquet A, Selle F, Fabbro M, Kalbacher E, Follana P, Lesoin A, Medioni J, Dupin J, Ferri RM, Bidard FC, Dubot C, Rouzier R, Joly Lobbedez F. Circulating tumor cells as prognostic marker in ovarian carcinoma: Results from the ANTHALYA study. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx372.017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
17
|
de La Motte Rouge T, Pouessel D, Benchikh A, Dubosq F, Durand X, Gillion N, Plantade A, Alexandre I, Thibault F. 7021 POSTER Multidisciplinary Management of Castration Resistant Prostate Cancer (CRPC) in France – a Survey Comparing Practices and Assessing Collaboration Between Urologists and Oncologists. Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)71972-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
18
|
Spano J, Chaïbi P, Vignot S, Thery JC, de La Motte Rouge T, Gil-Delgado M, Khayat D, Mouawad R. Age-related changes in plasma levels of inflamatory and angiogenic cytokins in patients with cancer. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e19699] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
19
|
Bidault F, Sahnoun M, de La Motte Rouge T, Rousseau V, Domont J, Massard C, Dhermain F, Ducreux D, Laplanche A, Caramella C, Canale S, Balleyguier C, Boulet B, Dromain C. High-grade gliomas treated with bevacizumab: Assessment of tumor response with functional MR. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e12505] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
20
|
Thariat J, Ray-Coquard IL, Thyss A, Italiano A, Sarini J, Miller RC, Bompas E, Brouchet A, Dassonville O, Salas S, Maingon P, Kurtz J, Reychler H, de La Motte Rouge T, Aldabbagh K, Usseglio J, Kerbrat P, Lotz J, Chaigneau L, Julieron M. Primary osteosarcomas of the mandible: Joint study of the Groupe Sarcome Francais (GSF), Rare Cancer Network, and Groupe d’Etude des Tumeurs de la Tete et du Cou (GETTEC). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.10036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
21
|
Motzer RJ, de La Motte Rouge T, Harzstark AL, Michaelson MD, Liu G, Gruenwald V, Ingrosso A, Tortorici MA, Bycott PW, Kim S, Rini BI. Axitinib second-line therapy for metastatic renal cell carcinoma (mRCC): Five-year (yr) overall survival (OS) data from a phase II trial. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.4547] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
22
|
Mouawad R, Spano J, Conforti R, Vignot S, de La Motte Rouge T, Khayat D. Evaluation of circulating angiopoietin levels with prognosis and disease progression in metastatic malignant melanoma. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.8522] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
23
|
Barrios Gonzales D, Loriot Y, Gomez-Roca C, Massard C, de La Motte Rouge T, Bahleda R, Soria J. Outcome of patients with rare tumors included in phase l clinical trials. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e13109] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
24
|
Loriot Y, Albiges-Sauvin L, Dionysopoulos D, Bouyon-Monteau A, Boyle H, You B, Massard C, de La Motte Rouge T. Why do residents choose the medical oncology specialty? Implications for future recruitment—results of the 2007 French Association of Residents in Oncology (AERIO) Survey. Ann Oncol 2010; 21:161-5. [DOI: 10.1093/annonc/mdp294] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
25
|
de La Motte Rouge T, Roca CG, Bahleda R, Gombos A, Pautier P, Soria J, Lhommé C, Massard C. 1252 Outcome and characteristics of patients with advanced gynaecological malignancies enrolled in phase I trials. EJC Suppl 2009. [DOI: 10.1016/s1359-6349(09)70464-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022] Open
|
26
|
Chinot O, de La Motte Rouge T, Moore N, Zeaiter A. 8713 Addition of bevacizumab to the multi-modality standard of care in patients with newly diagnosed glioblastoma: a phase III trial. EJC Suppl 2009. [DOI: 10.1016/s1359-6349(09)71687-8] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
27
|
de La Motte Rouge T, Pautier P, Duvillard P, Rey A, Morice P, Haie-Meder C, Kerbrat P, Culine S, Troalen F, Lhommé C. Long-term outcome and prognostic factors in 80 women treated for ovarian yolk sac tumor. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.5547] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
28
|
de La Motte Rouge T, Pautier P, Duvillard P, Rey A, Morice P, Haie-Meder C, Kerbrat P, Culine S, Troalen F, Lhommé C. Survival and reproductive function of 52 women treated with surgery and bleomycin, etoposide, cisplatin (BEP) chemotherapy for ovarian yolk sac tumor. Ann Oncol 2008; 19:1435-1441. [PMID: 18408223 DOI: 10.1093/annonc/mdn162] [Citation(s) in RCA: 64] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023] Open
Abstract
BACKGROUND Ovarian yolk sac tumor (YST) is a very rare malignancy arising in young women. Chemotherapy has dramatically improved the prognosis. Current treatment consists of surgery followed by bleomycin, etoposide, and cisplatin (BEP) chemotherapy. However, given the rarity of this tumor, ovarian YST-specific survival and outcome after such treatment are not precisely known. PATIENTS AND METHODS This report concerns prospectively recorded cases that were either treated at Institut Gustave Roussy (Villejuif, France) or referred there for advice about therapy. From 1990 to 2006, 52 patients underwent surgery followed by BEP chemotherapy. Data on patient characteristics, treatment, survival, and fertility outcome were analyzed to assess treatment efficacy and gonadal toxicity after achieving a complete remission. RESULTS Thirty-five patients had stage I/II tumors while 17 patients presented with stage III/IV disease. With a median follow-up of 68 months, the overall 5-year survival and disease-free survival rates were 94% and 90%, respectively. Forty-one women underwent fertility-sparing surgery. Pregnancy was achieved in 12 of 16 (75%) women who attempted conception. Overall, 19 pregnancies have been recorded. CONCLUSIONS BEP chemotherapy following fertility-sparing surgery is a very effective treatment of ovarian YSTs. Most of the patients who attempt conception after complete remission will have children.
Collapse
Affiliation(s)
| | - P Pautier
- Department of Medical Oncology, Institut Gustave Roussy, Villejuif
| | - P Duvillard
- Department of Biopathology, Institut Gustave Roussy, Villejuif
| | - A Rey
- Department of Biostatistics, Institut Gustave Roussy, Villejuif
| | - P Morice
- Department of Surgery, Institut Gustave Roussy, Villejuif
| | - C Haie-Meder
- Department of Radiotherapy, Institut Gustave Roussy, Villejuif
| | - P Kerbrat
- Centre Eugène Marquis, Université de Rennes 1, Rennes
| | - S Culine
- Centre Régional de Lutte Contre le Cancer Val d'Aurelle, Montpellier, France
| | - F Troalen
- Department of Biopathology, Institut Gustave Roussy, Villejuif
| | - C Lhommé
- Department of Medical Oncology, Institut Gustave Roussy, Villejuif.
| |
Collapse
|